Clinical trials: Borderline-resectable Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- ACCELERATE (NCT06574620)
- Testing
- Genetic testing, Optional biopsy, Tissue collection
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Cancer
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan \& 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a…
- Trial name
- NCT01397019
- Testing
- Oxaliplatin, irinotecan, 5-FU & leucovorin
- Where
- 3 sites in Denmark
- Volunteers
- 56 people
- Sponsor
- Per Pfeiffer
Pancreatic Neoplasms
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at the patient's tumor followed by more…
- Trial name
- NCT00833859
- Testing
- GTX (gemcitabine, docetaxel and capecitabine), stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT06673017
- Testing
- PTM-101
- Where
- 9 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- PanTher Therapeutics
Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
This phase II trial studies how well combination chemotherapy, gemcitabine hydrochloride, and radiation therapy before surgery works in treating patients with pancreatic cancer that has not spread to other places in the body and…
- Conditions
- Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01897454
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Albert Einstein College of Medicine
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
The goal of this prospective observational study is to learn about the clinical utility of dynamic ctDNA-based Minimal Residual Disease (MRD) monitoring in patients with borderline resectable pancreatic cancer undergoing…
- Trial name
- MRD (NCT07080021)
- Testing
- Standard Reagents, Pancreatic Cancer
- Where
- 2 sites in China
- Volunteers
- 119 people
- Sponsor
- Ruijin Hospital
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02427841
- Testing
- Fluorouracil, Gemcitabine, Image Guided Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Cancer, Adult
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. Led by The First Affiliated Hospital with Nanjing Medical University and Peking University Cancer Hospital \& Institute (as leading centers)…
- Trial name
- NOTABLE-309 (NCT07277452)
- Testing
- Nimotuzumab, AG regimen
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
This pilot and feasibility study studies how well nivolumab and combination chemotherapy work before surgery in treating patients with pancreatic cancer that could possibly be removed by surgery.
- Trial name
- NCT03970252
- Testing
- Fluorouracil, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Patients With Borderline Resectable Pancreatic Cancer
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study
FOLFIRINOX regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer.
- Trial name
- FIRINOX (NCT02148549)
- Testing
- FIRINOX
- Where
- 9 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Wakayama Medical University
Pancreatic Cancer
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
Phase II study of neoadjuvant treatment with Gemcitabine, Tarceva and Oxaliplatin followed by chemotherapy with Tarceva and Gemcitabine in patients with pancreatic adenocarcinoma with borderline resectability.
- Trial name
- NCT01531712
- Testing
- Gemcitabine, Radiotherapy, Tarceva
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Institut Català d'Oncologia
Pancreatic Cancer
The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.
To investigate the correlation between pretreatment ADC value of diffusion MRI and pathologic response in patients with borderline resectable pancreatic carcinoma who undergo neoadjuvant therapy.
- Trial name
- DIFFERENT (NCT02777463)
- Testing
- diffusion-weighted MRI
- Where
- Japan
- Volunteers
- 28 people
- Sponsor
- Wakayama Medical University
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects of losartan and hypofractionated radiation therapy after chemotherapy in treating patients with pancreatic cancer that may or may not be removed by surgery (borderline resectable) or…
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
- Trial name
- SHAPER (NCT04106856)
- Testing
- Hypofractionated Radiation Therapy, Losartan, Losartan Potassium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Utah
Pancreatic Adenocarcinoma
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling).
- Trial name
- NCT01726582
- Testing
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 229 people
- Sponsor
- Medical College of Wisconsin
Chemotherapy Effect, Pancreas Cancer
Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline
Unlike other types of gastrointestinal tumors, there is controversial evidence of the efficacy of neoadjuvant therapy in patients with borderline and resectable adenocarcinoma (ADK) of the pancreas, the objective of this study is…
- Trial name
- PaNLoCat (NCT05514171)
- Testing
- Neoadyuvant therapy
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital del Mar
Pancreatic Cancer
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer.
- Trial name
- NCT00761241
- Testing
- Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Locally Advanced Malignant Neoplasm
Chemoimmunotherapy and Radiation in Pancreatic Cancer
The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.
- Trial name
- CRIT (NCT01903083)
- Testing
- Tadalafil, Gemcitabine, Radiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Providence Health & Services
Pancreatic Cancer
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
- Trial name
- NCT02843945
- Testing
- Directional Brachytherapy Source Implant
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- CivaTech Oncology
Pancreas Cancer, Adenocarcinoma
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
Despite important therapeutic advances, pancreatic adenocarcinoma remains one of the cancers with a high mortality rate (4th leading cause of cancer death in the US in 2021), poor prognosis (5-year overall survival rate of 10%)…
- Trial name
- ReMeTTI (NCT05511116)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Pancreas Ductal Adenocarcinoma
Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
Based on the superior efficacy and safety profile of liposomal irinotecan over irinotecan in pancreatic cancer, as well as preliminary results from earlier studies evaluating nab-paclitaxel and gemcitabine (AG) combined with…
- Trial name
- NCT07806110
- Testing
- SHR-1701, liposomal irinotecan+nab-paclitaxel+gemcitabine
- Where
- China
- Volunteers
- 62 people
- Sponsor
- The First Hospital of Jilin University